Cargando…

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis

While most patients diagnosed with multiple myeloma (MM) receive initial therapy, reported attrition rates are high. Understanding attrition rates and characteristics of patients not receiving subsequent therapy is useful for MM stakeholders. We performed an analysis of attrition rates in a large di...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCurdy, Arleigh, Mian, Hira, LeBlanc, Richard, Jimenez-Zepeda, Victor H., Su, Jiandong, Masih-Khan, Esther, Visram, Alissa, Louzada, Martha, Song, Kevin, White, Darrell, Sebag, Michael, Stakiw, Julie, Reiman, Anthony, Aslam, Muhammad, Bergstrom, Debra, Kotb, Rami, Kaedbey, Rayan, Gul, Engin, Reece, Donna, Venner, Christopher P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359388/ https://www.ncbi.nlm.nih.gov/pubmed/37474492 http://dx.doi.org/10.1038/s41408-023-00883-x

Ejemplares similares

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
por: Côté, Julie, et al.
Publicado: (2023)

Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
por: Mian, Hira, et al.
Publicado: (2022)

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
por: Mian, Hira, et al.
Publicado: (2022)

The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
por: Cherniawsky, Hannah M., et al.
Publicado: (2020)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences
por: Pritlove, Cheryl, et al.
Publicado: (2021)

The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience
por: Figueiredo, Amarilis, et al.
Publicado: (2019)

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
por: Mian, Owais, et al.
Publicado: (2023)

Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
por: Sterrett, Russell, et al.
Publicado: (2021)

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
por: Mian, Hira, et al.
Publicado: (2023)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
por: Kis, Olena, et al.
Publicado: (2017)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
por: Benda, Magdalena A., et al.
Publicado: (2023)

Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study
por: Tessier, Camille, et al.
Publicado: (2021)

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
por: Cerchione, Claudio, et al.
Publicado: (2022)

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
por: Kumar, Shaji K., et al.
Publicado: (2013)

Vertebral compression fractures in multiple myeloma: redefining the priorities during the COVID-19 pandemic
por: Giorgi, P. D., et al.
Publicado: (2020)

Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case report
por: Alabdulbaqi, Manar, et al.
Publicado: (2020)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2021)

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
por: Fonseca, Rafael, et al.
Publicado: (2020)

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China
por: Tang, Wenjiao, et al.
Publicado: (2023)

Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
por: Alfarra, Helmi, et al.
Publicado: (2020)

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

P973: ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE
por: More’, Sonia, et al.
Publicado: (2023)

TAZ upregulates MIR‐224 to inhibit oxidative stress response in multiple myeloma
por: Abegunde, Samuel O., et al.
Publicado: (2023)

Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma
por: Chen, Yuxi, et al.
Publicado: (2018)

Gender disparities in multiple myeloma publications
por: Dweik, Aala, et al.
Publicado: (2022)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

P978: EVOLVING PATTERNS IN MULTIPLE MYELOMA TREATMENT ATTRITION RATES AND PROGRESSION THROUGH LINES OF THERAPY WITH MODERN CHEMOTHERAPY OPTIONS
por: Al-Kaisi, Firas, et al.
Publicado: (2023)

Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression
por: Visram, Alissa, et al.
Publicado: (2021)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
por: Reece, Donna, et al.
Publicado: (2012)

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
por: Kumar, Shaji, et al.
Publicado: (2022)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
por: Baljevic, Muhamed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_spipk7p361asdbgo2gjmmqsp06